19231-06-2

Usage

Uses

1. Used in Pharmaceutical Industry:
a. Bis(p-methoxyphenyl)iodonium bromide is used as a reactant for the preparation of thyroid hormone analogs, contributing to the development of medications targeting thyroid-related conditions.
b. It is also used as a reactant in the synthesis of analogs of clofibrate and clobuzarit, which are relevant in the treatment of various medical conditions, including dyslipidemia and cardiovascular diseases.
2. Used in Research and Development:
a. Bis(p-methoxyphenyl)iodonium bromide serves as an inhibitor of amino acid utilization, making it a valuable tool in studying the metabolic pathways and functions of amino acids in various biological systems.
3. Used in Chemical Synthesis:
a. As a diphenyliodonium compound, bis(p-methoxyphenyl)iodonium bromide is utilized in the synthesis of various organic compounds, contributing to the advancement of chemical research and the development of new materials and products.

Flammability and Explosibility

Notclassified

InChI:InChI=1/C14H14IO2.BrH/c1-16-13-7-3-11(4-8-13)15-12-5-9-14(17-2)10-6-12;/h3-10H,1-2H3;1H/q+1;/p-1

Upstream product

• 100-66-3 methoxybenzene 
• 696-62-8 para-iodoanisole 

Downstream Products

• 83249-56-3 N-acetyl-O-(4-methoxyphenyl)-3,5-diiodo-L-tyrosine ethyl ester 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 696-62-8 para-iodoanisole 
• 60200-81-9 3,3,3-Trifluoro-2-(4-methoxy-phenoxy)-2-trifluoromethyl-propionic acid ethyl ester 
• 111088-56-3 3,5-diiodo-O-methyl-N-(trifluoroacetyl)-L-thyronine methyl ester 
• 591-50-4 iodobenzene 
• 2132-80-1 4,4'-Dimethoxybiphenyl 
• 7444-01-1 N-Acetyl-3-<3,5-diiod-4-(4-methoxy-phenoxy)-phenyl>-2-methyl-alanin-aethylester 
• 5680-97-7 N-Trifluoracetyl-3-<3,5-diiod-4-(4-methoxy-phenoxy)-phenyl>-2-methyl-alanin-aethylester 
• 19103-38-9 3,5-diisopropyl-4-(4-methoxy-phenoxy)-benzaldehyde 
• 60636-95-5 2-(4-methoxyphenyl)-5-phenyltetrazole 
• 456-84-8 3,5-diiodo-N-(trifluoroacetyl)-L-thyronine methyl ester 
• 111087-98-0 (S)-2-Amino-3-[4-(3-formyl-4-hydroxy-phenoxy)-3,5-diiodo-phenyl]-propionic acid 
• 111087-80-0 (S)-2-Amino-3-[4-(4-hydroxy-3-hydroxymethyl-phenoxy)-3,5-diiodo-phenyl]-propionic acid 

Relevant academic research and scientific papers

One-pot preparations of diaryliodonium bromides from iodoarenes and arenes, with sodium perborate as the oxidant

This paper reports a one-pot synthesis of the title bromides from both activated and deactivated iodoarenes which are first oxidized with anhydrous NaBO3·H2O/Ac2O/conc.H2SO 4 liquid mixtures, then coupled in situ with benzene and activated arenes and, finally, precipitated out with a KBr solution; this method is easy, cheap, safe and fairly effective.

Thyroid Hormone Analogues. Synthesis of 3'-Substituted 3,5-Diiodo-L-thyronines and Quantitative Structure-Activity Studies of in Vivo Thyromimetic Activities in Rat Liver and Heart

Twenty-nine 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) have been synthesized by using established methods and by new route involving manipulation of a 3'-formyl intermediate.In vitro hormone receptor binding (to intact nuclei) and in vivo thyromimetic activity (induction of mitochondrial 3-phosphoglycerate oxidoreductase, GPDH) were measured in rat liver and heart for these new analogues and for the 18 previously reported 3'-substituted 3,5-diiodo-L-thyronines.Analysis of the binding data using theoretical conformational and quantitative structure-affinity methods implies that the 3'-substituent recognition site on the thyroid hormone receptor is hydrophobic and limited in depth to the length of the natural iodo substituent, but has sufficient width to accomodate a phenyl or cyclohexyl group.Receptor binding is reduced by approximately 10-fold in 3'-acyl derivatives which form strong intramolecular acceptor hydrogen bonds with the ajacent 4'-hydroxyl.The compounds studied showed no differences in their relative affinities for heart and liver nuclei, suggesting that receptors in these tissues are similar.However, the relationships between thyromimetic activity (induction of GPDH) and nuclear binding showed some tissue differences.A high correlation between activity and binding is observed for full agonists in the heart, but an equally significant correlation for the liver data is only seen when 3'-substituent bulk (molar reactivity) is included in the analysis.These results suggest the possibility that differential tissue penetration or access to receptors may occur in vivo.